Article Text
Editorial
Dronedarone for the treatment of non-permanent atrial fibrillation: National Institute for Health and Clinical Excellence guidance
Statistics from Altmetric.com
Footnotes
-
Competing interests Both authors have acted as advisors to Sanofi.
-
Provenance and peer review Commissioned; internally peer reviewed.